Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* If female and of childbearing potential, subject has a negative pregnancy test and is not nursing.~* If female and of childbearing potential, subject is using adequate birth control for the duration of the study.~* Subject is able to understand and comply with study procedures.~* Subject is a non-smoker.~* Subject consumes no more than 1 alcoholic drink per day.~* Subject agrees to refrain from alcohol consumption for 48 hours prior to each drug administration and 48 hours after each drug administration.~* Subject is able and willing to provide written informed consent prior to any study procedures being performed.~Exclusion Criteria:~* Subject has abnormal screening/baseline laboratory parameters deemed to be clinically significant by the Investigator.~* Subject has taken any prescription medications other than hormone replacement therapy or thyroid replacement hormones within 3 days prior to drug administration.~* Subject has taken any of the following medications within 2 weeks prior to study entry:~  * NSAIDs or other medications for pain, including aspirin or aspirin containing products and acetaminophen (see Appendix B of protocol in Appendix 16.1.1)~ * Proton pump inhibitors, including Prilosec®, Prevacid®, Aciphex®, Protonix®, or Nexium®~ * H-2 blockers, including Tagamet®, Zantac®, Axid®, or Pepcid®~ * Any antiplatelet agent, including Plavix®, Ticlid®, Pletal®, ReoPro®, Integrilin®, Aggrastat®, or Persantine®~ * Any anti-coagulant, including Coumadin®, Acenocoumarol, Phenprocoumon, Phenindione, Heparin, Exanta®, Argatroban, Lepirudin, Hirudin or Bivalirudin~* Subject has used an investigational agent within the past 30 days.~* Subject has hypersensitivity or contraindications to aspirin, ibuprofen, or other NSAID.~* Subject has sensitivity to lecithin.~* Subject has a history of gastrointestinal problems including ulcers, frequent indigestion, or heartburn.~* Subject has a history of stroke, myocardial infarction, or congestive heart failure.~* Subject has a history of asthma, other bronchospastic activity, nasal polyps, or angioedema other than resolved childhood asthma.~* Subject has a history of kidney or liver disease.~* Subject has a history of thrombocytopenia, neutropenia, or bleeding disorder.~* Subject has a history of coronary arterial bypass.~* Subject has a history of non-trauma related hemorrhage.~* Subject has a history of chronic hypertension.~* Subject is currently enrolled in another investigational trial.~* Subject's platelets are unresponsive to arachidonic acid

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PL-ASA 325 mg (Type: EXPERIMENTAL): Novel aspirin formulation being tested
- IR 325 mg (Type: ACTIVE_COMPARATOR): Immediate release aspirin
- PL-ASA-650 (Type: EXPERIMENTAL): Novel aspirin formulation being tested
- IR 650 (Type: ACTIVE_COMPARATOR): Immediate release aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete